European startups at the forefront of the fight against cancer

With nearly 1,500 entities, Europe hosts a larger number of cancer-related startups than the US

04-Feb-2025 - Cancer remains a major health threat in Europe, which accounts for nearly 25% of global cases and over 20% of deaths, despite having less than 10% of the world's population[1]. Technological advancements are improving survival rates, with European healthcare systems showcasing excellence in ...

Dissolving clusters of cancer cells to prevent metastases

Digoxin, a substance found in foxgloven, dissolves clusters of circulating cancer cells in the blood, thus reducing the risk of metastases formation

28-Jan-2025 - Certain tumour types do not remain at their point of origin but spread throughout the body and form metastases. This is because the primary tumour continuously releases cancer cells into the blood. These circulating tumour cells (CTCs) can join together into small clusters of up to a dozen cells ...

BioMed X Institute launches new cancer collaboration with Daiichi Sankyo

Call for proposals from researchers around the world to take part in this ambitious project

15-Jan-2025 - BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced the launch of a new collaboration with Daiichi Sankyo Co., Ltd., a global pharmaceutical company headquartered in Japan. This collaboration marks the start of a cutting-edge initiative to explore ...

Araris Biotech announces research collaboration and option to license agreement with Chugai Pharmaceutical Co.

Araris to receive an upfront fee and milestone payments potentially totalling USD 780 million plus royalties on net product sales

15-Jan-2025 - Araris Biotech AG, a Swiss oncology biotech spin-off company developing next-generation antibody drug conjugates (ADCs), announced they have entered a Research Collaboration and Option to License Agreement (“RCO”) under which Araris will use its proprietary linker-conjugation platform, AraLinQ™, ...

Merck Reiterates Confidence in Returning to Sustainable Growth

Tailwind thanks to robust global growth trends in all three business sectors

18-Oct-2024 - Merck is looking confidently toward the future. At the Capital Markets Day, the company shared its expectation of profitable and financially strong growth in the coming years. After the transitional year of 2023, Merck considers the medium-term growth opportunities in its markets to be intact. ...

ImmunOs Therapeutics raises $11 million and further strengthens investor base

“ImmunOs Therapeutics has a very innovative approach to target myeloid checkpoints which are potentially the next major breakthrough in immuno-oncology”

24-Sep-2024 - ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its unique immune system modulating HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, announced the closing of a Series C financing round of $11 million. The ...

PhoreMost extends Series B financing to $50M to advance high-value oncology and inflammation degrader programmes

16-Sep-2024 - PhoreMost Ltd. announced it has added USD $12 million to its Series B financing, bringing the total raised to over $50 million. The additional investment was led by Parkwalk Advisors, the largest growth EIS fund manager, with participation from existing investors BGF, Dr Jonathan Milner, Amadeus ...

Myricx Bio raises £90 million ($114 million) Series A financing

Michael Bauer from Novo Holdings and Lucille Conroy from Abingworth will join Myricx Bio Board of Directors

16-Jul-2024 - Myricx Bio, a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), announced the closing of its series A financing raising £90m ($114m). The round was co-led by new leading life science investors Novo Holdings ...

APEIRON Biologics to be Acquired by Ligand Pharmaceuticals for USD 100 Million

Ligand also commits to invest up to USD 4 million in APEIRON spin-off, invIOs

10-Jul-2024 - APEIRON Biologics AG announced that its shareholders have entered into a definitive agreement to sell their APEIRON shares to US-based Ligand Pharmaceuticals Incorporated for USD 100 million. APEIRON shareholders are also entitled to additional consideration based on future commercial and ...

Bavarian biotechnology grows and achieves record financing

11 start-ups and two relocations show start-up momentum

09-Jul-2024 - At this year's BayOConnect conference, BioM presented his latest annual report "Biotech in Bavaria 2023/24 - Incubating Science for Health". With the report, the Biotech Cluster Development Organization presented the current biotech figures as well as developments and successes of the Bavarian ...